SCHEMBL6451058

SCHEMBL6451058

Cc1cn(-c2cc(C(=O)Nc3ccc(C)c(NC(=O)n4ccc5c(N6CCOCC6)ncnc54)c3)cc(C(F)(F)F)c2)cn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.61
POLB P06746 1/20 0.61
RECQL P46063 1/20 0.61
CSF1R P07333 6/20 0.57
MAPT P10636 1/20 0.53
ABL1 P00519 3/20 0.52
BCR P11274 2/20 0.52
MAPK14 Q16539 1/20 0.50
BRAF P15056 6/20 0.49
RAF1 P04049 4/20 0.49
EPHB2 P29323 1/20 0.47
LYN P07948 2/20 0.47
EGFR P00533 1/20 0.46
LCK P06239 1/20 0.46
FYN P06241 1/20 0.46
YES1 P07947 1/20 0.46
HCK P08631 1/20 0.46
SRC P12931 1/20 0.46
PDGFRA P16234 1/20 0.46
FRK P42685 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6454440 0.88 CSF1R (0.54) CSF1RMAPK14BRAFRAF1LYN
SCHEMBL6451027 0.87 KDM4E (0.64) KDM4EPOLBRECQLCSF1RMAPT
SCHEMBL6450886 0.86 CSF1R (0.65) KDM4EPOLBRECQLCSF1RMAPT
SCHEMBL6455319 0.83 KDM4E (0.59) KDM4EPOLBRECQLCSF1RMAPT
SCHEMBL6451135 0.82 KDM4E (0.58) KDM4EPOLBRECQLCSF1RMAPT
SCHEMBL14216517 0.82 KDM4E (0.57) KDM4EPOLBRECQLCSF1RMAPT
SCHEMBL6450014 0.82 KDM4E (0.57) KDM4EPOLBRECQLCSF1RMAPT
SCHEMBL6451143 0.81 KDM4E (0.64) KDM4EPOLBRECQLCSF1RMAPT
SCHEMBL6450942 0.81 KDM4E (0.57) KDM4EPOLBRECQLCSF1RMAPT
SCHEMBL6450943 0.81 KDM4E (0.56) KDM4EPOLBRECQLCSF1RMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050159391-A1 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2005-07-21 US claimed
US-20080108616-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-05-08 US disclosed
US-20080108616-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-05-08 US disclosed
US-7338957-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2008-03-04 US disclosed
US-7338957-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2008-03-04 US disclosed
US-20050159391-A1 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2005-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108616-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS LCK, FYN, BMX KDM4E 3165/4885POLB 4460/4885RECQL 3252/4885
US-20050159391-A1 Compounds and compositions as protein kinase inhibitors LCK, FYN, BMX KDM4E 3165/4885POLB 4460/4885RECQL 3252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.